Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31970| Title: | Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer. | Austin Authors: | Loft, Matthew;Lok, Sheau Wen;De Boer, Richard;Malik, Laeeq;Greenberg, Sally;Yeo, Belinda ;Anton, Angelyn;Nottage, Michelle;Wong, Vanessa ;Nott, Louise;Collins, Ian M;Torres, Javier;Barnett, Frances;Lombard, Janine M;Gibbs, Peter;Gately, Lucy | Affiliation: | Division of Personalised Oncology, Walter and Eliza Hall, 1G Royal Pde, Parkville, VIC, 3052, Australia. Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, VIC, Australia. Department of Medical Oncology, Canberra Hospital, Garran, ACT, Australia. Department of Medical Oncology, Western Health, Footscray, VIC, Australia. Medical Oncology Division of Personalised Oncology, Walter and Eliza Hall, 1G Royal Pde, Parkville, VIC, 3052, Australia. Department of Medical Oncology, Royal Brisbane Hospital, Herston, QLD, Australia. Department of Medical Oncology, Royal Hobart Hospital, Hobart, TAS, Australia. Department of Medical Oncology, South West Healthcare, Warrnambool, VIC, Australia. Department of Medical Oncology, Goulburn Valley Health, Shepparton, VIC, Australia. Department of Medical Oncology, Northern Hospital, Epping, VIC, Australia. Department of Medical Oncology, Newcastle Private Hospital, New Lambton Heights, NSW, Australia. |
Issue Date: | Feb-2023 | Date: | 2023 | Publication information: | Breast Cancer Research and Treatment 2023; 198(1) | Abstract: | Dual anti-HER2 targeted therapy and chemotherapy is the current first-line standard of care for HER2 + metastatic breast cancer (MBC), with endocrine therapy (ET) the backbone of treatment in hormone receptor positive (HR +) disease. The potential ET benefit in HER2 + /HR + patients is unknown as pivotal dual anti-HER2 clinical trials precluded ET use. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31970 | DOI: | 10.1007/s10549-022-06856-1 | ORCID: | 0000-0003-3267-4520 |
Journal: | Breast Cancer Research and Treatment | PubMed URL: | 36624321 | ISSN: | 1573-7217 | Type: | Journal Article | Subjects: | Endocrine therapy HER2 Hormone receptor-positive Metastatic breast cancer |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.